Everolimus (Afinitor, Zortress) — Research Compounds Library | RetatrutideCompare

mTORC1 inhibitor derived from sirolimus. FDA-approved for several oncology indications and as an immunosuppressant. Low-dose intermittent regimens are studied for immunosenescence (Mannick 2014, 2018).